Ovarian Cancer

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Deena M. Atieh Graham, MD, discusses ongoing studies of note in patients with ovarian cancer following World Ovarian Cancer Day.

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja) for select KRAS-mutated recurrent low-grade serous ovarian cancer.

Deena M. Atieh Graham, MD, highlights the current treatment paradigm in ovarian cancer, particularly PARP inhibitors and new ADCs in the space.

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.

INX-315 has received FDA fast track designation for the treatment of patients with CCNE1-amplified, platinum-resistant or refractory ovarian cancer.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Elizabeth K. Lee, MD, discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer.

Hyun Woong Cho, MD, PhD, explains the rationale for assessing niraparib/bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.

Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

SON-1010 plus atezolizumab was safe and showed clinical activity in platinum-resistant ovarian cancer and other advanced solid tumors.

Tashanna K. Myers, MD, discusses the importance of telling patients with ovarian cancer about the HRQOL outcomes associated with mirvetuximab soravtansine.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss ongoing research and areas of potential investigation in ovarian cancer.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss updates in ovarian cancer from the 2025 SGO Annual Meeting.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.